On Jul. 28, 2020, Reata Pharmaceuticals announced that researchers at NYU Grossman School of Medicine (NYU) initiated an Investigator-Sponsored Trial, known as BARCONA, to study the effect of bardoxolone methyl (ﾓbardoxoloneﾔ) in patients suffering from COVID-19. At NYUﾒs request, Reata is providing drug supply for the trial. NYU will initiate the Phase 2 BARCONA study with a primary endpoint of safety.